Neil Bodick - Flexion Therapeutics Insider

FLXN -- USA Stock  

USD 28.14  0.56  2.03%

Chief Medical Officer & Co-Founder

Dr. Neil Bodick, M.D., Ph.D. serves as Chief Scientific Officer of the Company. He was Chief Medical Officer of Flexion Therapeutics, Inc. Previously, Dr. Bodick was at Eli Lilly and Company, where he founded Chorus and served as Chief Medical Officer and Chief Operating Officer. Prior to that, Dr. Bodick was responsible for earlyphase clinical investigation at Lilly Research Laboratories. He also was Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the development of computerbased systems to support imageintensive diagnosis. Dr. Bodick holds 13 patents in the areas of neuroscience and computer science and is the recipient of the Biomedical Research Service Award and the New Investigator Research Award from the National Institutes of Health.
Age: 69  Founder Since 2017      

Neil Bodick Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (30.11) % which means that it has lost $30.11 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (79.84) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 159.56 M in liabilities with Debt to Equity (D/E) ratio of 71.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Flexion Therapeutics has Current Ratio of 15.26 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company was founded in 2007 and is headquartered in Burlington, Massachusetts. Flexion Therapeutics operates under Drug Manufacturers - Specialty Generic classification in USA and traded on NASDAQ General Markets. It employs 255 people.Flexion Therapeutics (FLXN) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 255 people. Flexion Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Flexion Therapeutics Leadership Team

David Arkowitz, CFO, MBA
Sandesh Mahatme, Director
Scott Canute, Director, MBA
Mark Levine, President
Dan Thornton, President, MBA
John Magee, President, MBA
Neil Bodick, Founder
Mark Fraga, President
Michael Clayman, CEO
Ann Merrifield, Director
Alan Milinazzo, Director
Jon Mahlowitz, VP
Frederick Driscoll, CFO
Heath Lukatch, Director
Patrick Mahaffy, Chairman
Samuel Colella, Director, MBA
Yamo Deniz, Executive, Ph.D
Mark Stejbach, Director, MBA
Scott Kelley, President

Stock Performance Indicators

Did you try this?

Run Fundamentals Comparison Now

Fundamentals Comparison

Compare fundamentals across multiple equities to find investing opportunities
All  Next Launch Fundamentals Comparison

Generate Optimal Portfolios

Align your risk and return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally see Investing Opportunities. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.